Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $670,800.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total transaction of $670,800.00. Following the completion of the transaction, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,180,820.35. This represents a 6.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Andrew Guggenhime also recently made the following trade(s):

• On Tuesday, January 21st, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00.
• On Wednesday, December 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $88.78, for a total transaction of $710,240.00.

Vaxcyte Stock Performance

PCVX stock opened at $79.74 on Friday. The firm has a market cap of $9.94 billion, a PE ratio of -17.33 and a beta of 0.98. The firm’s 50 day moving average price is $85.61 and its 200-day moving average price is $94.62. Vaxcyte, Inc. has a one year low of $58.10 and a one year high of $121.06.

Institutional Trading of Vaxcyte

Institutional investors have recently made changes to their positions in the company. Whipplewood Advisors LLC purchased a new stake in shares of Vaxcyte during the 4th quarter valued at approximately $28,000. Blue Trust Inc. raised its position in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after buying an additional 93 shares during the period. Smartleaf Asset Management LLC raised its position in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after buying an additional 260 shares during the period. National Bank of Canada FI acquired a new stake in Vaxcyte in the 4th quarter valued at approximately $41,000. Finally, Meeder Asset Management Inc. increased its holdings in Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after purchasing an additional 635 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $14.00 target price on shares of Vaxcyte in a research note on Tuesday, February 11th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Vaxcyte currently has an average rating of “Buy” and a consensus price target of $127.71.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.